12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation - Université de Rennes Access content directly
Journal Articles Hepatology Year : 2018

12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Victor de Ledinghen
Nassim Kamar
Vincent Leroy
Vincent Di Martino
Valérie Canva
  • Function : Author
Filomena Conti
  • Function : Author
Jerome Dumortier
Hélène Montialoux
  • Function : Author
Pascal Lebray
  • Function : Author
Danielle Botta-Fridlund
  • Function : Author
Albert Tran
  • Function : Author
Camille Besch
Philippe Perre
  • Function : Author
Stéphane Chevaliez
  • Function : Author
Georges-Philippe Pageaux

Abstract

Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).
No file

Dates and versions

hal-01807755 , version 1 (05-06-2018)

Identifiers

Cite

Pauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, Caroline Jezequel, Christophe Duvoux, et al.. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. Hepatology, 2018, 68 (4), pp.1277-1287. ⟨10.1002/hep.29918⟩. ⟨hal-01807755⟩
88 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More